Stock Guru Profile GeneThera, Inc. (OTCBB:GTHA)
If you have been following our reports on GeneThera (GTHA) you know there is quite a story to tell. This is one of the extremely rare companies addressing Mad Cow Disease. Now others will be reading this story. GTHA has announced that it will be the main subject of a Media Campaign being led by InvestInItaly. Aren’t you glad you read about GTHA here first!
InvestInItaly has designed a press program that will feature GeneThera and its collaboration with IZSLER as previously announced. The campaign will feature GeneThera and a quote from Dr. Tony Milici, CEO, and be published in various magazines and journals such as Les Echos, Le Monde, Le Figaro, La Tribune, Handelsblatt, L’Express, Investir, Le Pointe, L’usine Nouvelle, Nature, Science, Scrip WP Newsletter, Chemistry Today and New Scientist. Many of these publications have a worldwide reach.
Creekstone Farms, a Kansas beef producer, wanted to reassure customers that its cattle are safe to eat by testing them all for Mad Cow Disease. Mad Cow Disease impacts humans and can have a fifty year incubation period. Children born in the 80’s are particularly at risk. This is a brave and important company that has allied itself with IZLER for the purpose of participating in Phase II Clinical Trials in Italy because the FDA has refused to allow any entity to test for Mad Cow Disease — even when one producer of cattle decided to assure their purchasers of a Mad Cow Disease Free herd, the FDA stepped in to resurrect a 1913 law to prohibit testing for Mad Cow Disease. Link Here to that story in USA Today.
SOURCE: GeneThera, Inc. and Dr. Milici
CONTACT: GeneThera, Inc.
Dr. Tony Milici, 303-463-6371
http://www.genethera.net
Source:
GTHA – GeneThera, Inc.
Dr. Antonio Milici, CEO
GeneThera, Inc.
3930 Youngfield St.
Wheat Ridge, CO 80033
Fax: (303) 463 – 6377
About GeneThera, Inc. GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne’s Disease, diseases affecting cattle worldwide.
About IZSLER Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna (IZSLER),(www.bs.izs.it), offers a broad range of services in the Public Veterinary sectors in particular, Food Safety to the Veterinary Services, Breeders and Consumers. Its functions today can be described as those of a Technical-Scientific Body providing services as required of it by national and regional law. At the present, IZSLER employs over 600 persons, 90 of them are graduated scientists (veterinarians, biologists and chemists). On a regional basis (Lombardia and Emilia Romagna), IZSLER performs diagnosis for a variety of viral infectious diseases of ruminants, pigs, horses, poultry and other species of economic interest (rabbits, fishes, bees….), and microbiological and chemical analysis on foodstuffs of animal origin destined for human consumption and on food resources for animals.
“Safe Harbor” Statement: Certain statements in this release are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company’s ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
Forward Loooking Statement: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .
Disclosure: Pentony Enterprises LLC: was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment advisers or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.
